^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTNNB1 S45P

    i
    Entrez ID:
    1499
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (PEPN2011) (NCT04851119)
    Phase 1/2
    Children's Oncology Group
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    11/08/2021
    Primary completion :
    06/30/2028
    Completion :
    06/30/2028
    RNF43 • CTNNB1 • TCF7L2
    |
    APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P
    |
    tegavivint (BC2059)